A5091310395- Ovarian cancer diagnosis and treatment
- PARP inhibition in cancer therapy
- Uterine Myomas and Treatments
- Bone health and osteoporosis research
- Intraperitoneal and Appendiceal Malignancies
- Bone Metabolism and Diseases
- Thyroid and Parathyroid Surgery
- Intestinal and Peritoneal Adhesions
- Bone health and treatments
Jikei University School of Medicine
2024
Noguchi Hospital
2024
Katsushika Medical Center
2023
This study compared the effectiveness, safety, and tolerability of dose-dense paclitaxel carboplatin plus bevacizumab (ddTC+Bev) with ddTC for advanced ovarian cancer.
Abstract Aim To investigate the effects of surgical menopause on bone mineral density and quality because bilateral salpingo‐oophorectomy for treatment gynecological malignancies is common even in premenopausal patients. This study prospective one measurements after surgery perimenopausal gynecologic malignancies. Methods In 50 women who underwent a diagnosis malignancies, (BMD), blood levels tartrate‐resistant acid phosphatase 5b (TRACP‐5b) bone‐specific alkaline (BAP) as metabolism...
Laparoscopic surgery has become a widely accepted standard for treating benign gynecological conditions in recent years. Total laparoscopic hysterectomy (TLH) is one of these procedures, which performed at numerous medical institutions. Compared to total abdominal (TAH), TLH offers less invasive approach, leading reduced postoperative pain, shorter hospital stay and quicker reintegration into society. However, the extensive use electric scalpels energy devices confined spaces increases risk...
Objective:We report final primary endpoint in the original cohort of Korean Gynecologic Oncology Group (KGOG) 3046 study on neoadjuvant chemotherapy (NAC) with dual immune checkpoint blockade (durvalumab and tremelimumab) newly diagnosed advanced-stage epithelial ovarian cancer (EOC).Methods: This enrolled patients International Federation Gynecology Obstetrics stage IIIC-IV EOC.Enrolled received following chemo-immunotherapy [D] 1,500 mg q3w+tremelimumab 75 q3w+paclitaxel 175 mg/ m 2...
目的：腟断端細胞診の品質向上を目的に，口腔内細胞採取器具であるオーセレックスブラシRTと BD SurePathTM（SP）法を用い検体適否を検討した．